drugset / Trial / NCT06896110
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.
Timeline
- Start
- 2025-06-05
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 5 mg | Intrathecal |
| Subject | Azacitidine | Other / unclassified | 10 mg | Intrathecal |
| Subject | Azacitidine | Other / unclassified | 20 mg | Intrathecal |
| Subject | Azacitidine | Other / unclassified | 40 mg | Intrathecal |
| Subject | Nivolumab | Monoclonal antibody | 40 mg | Intrathecal |